Portola Pharmaceuticals

Portola Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops therapeutics for acute and chronic cardiovascular and autoimmune/inflammatory diseases. The company's products include PRT054021, an oral factor Xa inhibitor for the prevention and treatment of deep vein thrombosis and pulmonary embolism after orthopedic surgery; for stroke prevention in patients with atrial fibrillation; and for secondary prevention of myocardial infarction and stroke. Its products also include PRT060128, an oral and intravenous ADP receptor antagonist for the treatment of patients with acute coronary syndrome; for the prevention of cardiovascular events in patients undergoing percutaneous coronary intervention; and for secondary prevention of myocardial infarction and stroke. In addition, the company's products include PRT062607, an oral Syk-specific kinase inhibitor for treating chronic inflammatory diseases and Rheumatoid Arthritis (RA) which is used to treat certain cancers including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Portola Pharmaceuticals, Inc. was founded in 2003 and is based in South San Francisco, California.

MENLO PARK, Calif.--(BUSINESS WIRE)--Frazier Life Sciences announced the addition of Tao Fu as a Venture Partner. He has over 25 years of business development, general management, operations, strategy, and commercial leadership experience in the pharmaceutical and biotech industry. Mr. Fu most recently served as President & Chief Operating Officer and then Chief Strategy Officer for Zai Lab, a publicly-traded biotech company listed on both NASDAQ (ZLAB) and Hong Kong, where he held a broad

Frazier Life Sciences Adds Highly Experienced Biopharmaceutical Executive to Team

SOUTH SAN FRANCISCO, Calif., May 18, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that, due to the public health impact of the coronavirus (COVID-19) pandemic and to prioritize the health and well-being of stockholders, employees and other meeting...

Portola Pharmaceuticals Announces Virtual 2020 Annual Stockholder Meeting

Portola Pharmaceuticals - This Name You Haven't Heard Of Is The Next Big COVID-19 Company

SOUTH SAN FRANCISCO, Calif., May 14, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has proposed extending the New Technology Add-on Payment (NTAP) for Andexxa® [coagulation factor Xa (recombinant),...

U.S. Centers for Medicare & Medicaid Services (CMS) Proposes Extending New Technology Add-on Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa® for Third Year

Portola Pharmaceuticals (PTLA) delivered earnings and revenue surprises of -18.92% and -26.45%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Portola Pharmaceuticals (PTLA) Reports Q1 Loss, Misses Revenue Estimates

Alexion Pharmaceuticals made a move to acquire Portola Pharmaceuticals.

Why Portola Pharmaceuticals Is Skyrocketing Today

Portola Pharmaceuticals Inc. (NASDAQ: PTLA) shares more than doubled on Tuesday after the company announced that it would be acquired by Alexion Pharmaceuticals Inc.

Why Portola Stock Is Tuesday’s Big Winner

Alexion Pharma

Alexion Pharmaceuticals pledged to buy Portola Pharmaceuticals on Tuesday in a deal that combines two blood disease-focused biotech companies. Alexion stock slipped, but Portola stock flew.

Biotech Giant Alexion Swipes Blood Disease-Focused Portola In Buyout

Portola Pharmaceuticals, Inc. (PTLA) CEO Scott Garland on Q4 2019 Results - Earnings Call Transcript

Investors need to pay close attention to Portola Pharmaceuticals (PTLA) stock based on the movements in the options market lately.

Implied Volatility Surging for Portola Pharmaceuticals (PTLA) Stock Options

Portola: Still Bleeding, What I'm Looking For Before Buying It Back

Investors ran away after the business provided preliminary full-year 2019 results.

Here's Why Portola Pharmaceuticals Fell as Much as 45.4% Today

Shares of Portola Pharmaceuticals Inc. PTLA, -43.25% tumbled 45% in trading on Friday after the company shared "disappointing" preliminary fourth-quarter revenue for Andexxa, its antidote for patients treated with anticoagulants.

Portola's stock falls on weak Andexxa sales

Intuitive Surgical

KB Home

NortonLifeLock

Moderna

Take a look at the companies making headlines after the bell.

Stocks making the biggest moves after the bell: KB Home, Intuitive Surgical, NortonLifeLock and more

Cara Therapeutics

NanoString Technologies

These three small companies have the potential to make you a lot of money.

3 Small-Cap Healthcare Stocks With Large-Cap Potential

Amarin Corporation Plc

Tandem Diabetes Care

If you want to see your investment in the biotech market grow two-fold, these are the top stocks to buy.

3 Biotech Stocks That Can Double Your Money in 2020

AstraZeneca

Novartis

These three healthcare companies have a lot of good signs going for them.

3 'Top Healthcare' Stocks to Buy Now

Portola Pharmaceuticals' (PTLA) CEO Scott Garland on Q3 2019 Results - Earnings Call Transcript

Portola Pharmaceuticals (PTLA) delivered earnings and revenue surprises of 35.37% and 6.78%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Portola Pharmaceuticals (PTLA) Reports Q3 Loss, Tops Revenue Estimates

Portola Pharmaceuticals (PTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Portola Pharmaceuticals (PTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Portola has sidelined Bevyxxa after failing to secure its approval in Europe and focused its attention on Factor Xa reversal agent Andexxa.

Portola Could Have Big-Pharma Backed 'Blockbuster' Drug On Its Hands

What should investors think of this biotech stock and its signature drug candidate Andexxa?

Is Portola Pharmaceuticals a Buy?

The company's second-quarter revenue is sparking optimism for future growth.

Why Portola Pharmaceuticals Is Rocketing 10.9% Higher Today

Portola Pharmaceuticals, Inc. (PTLA) CEO Scott Garland on Q2 2019 Results - Earnings Call Transcript

Portola Pharmaceuticals (PTLA) delivered earnings and revenue surprises of 12.38% and 17.04%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

News for Portola Pharmaceuticals Stock (PTLA)